Nephrology Medical News about Eculizumab

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment

5. Debunking Myths in the US Healthcare System

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Complement Inhibitor Eculizumab in Atypical Hemolytic Uremic Syndrome
Clinical Journal of the American Society of Nephrology, 08/06/09

Mache CJ et al. – In this patient, complement inhibition by eculizumab temporarily terminated the microangiopathic hemolytic activity. Nevertheless, renal damage as a result of preceding and subsequent aHUS activity resulted in end–stage renal failure; therefore, therapeutic success may depend on early administration of eculizumab. The optimal duration of treatment may be variable and remains to be determined.

<< Previous
Phase II Study of Sorafenib in Patients With Sunitinib-Refractory...

Next >>
Chronic Renal Insufficiency Cohort (CRIC) Study: Baseline...

Severe atypical HUS caused by CFH S1191L--case presentation and review of treatment options
Pediatric Nephrology, 11/04/09 Relevance Score: 85%

Maintenance of Kidney Function Following Treatment With Eculizumab and Discontinuation of Plasma Exchange After a Third Kidney Transplant for Atypical Hemolytic Uremic Syndrome Associated With a CFH Mutation
American Journal of Kidney Diseases, 10/29/09 Relevance Score: 83%